Drugs / Anti-CD7 CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04599556 | Apr 2021 → Dec 2023 | acute leukemia, lymphoma | Zhejiang University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05454241 | Sep 2022 → Aug 2024 | hematopoietic and lymphoid cell neoplasm | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD7 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05454241 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor Cell Therapy” NCT04599556 ↗ |
| Target | CD7 | “anti-CD7 CAR-T” NCT04599556 ↗ |